未來股份(600532.SH)與濟南高新簽署戰略合作框架協議 開拓醫療領域業務
格隆匯1月25日丨未來股份(600532.SH)公佈,2021年1月25日,公司與濟南高新發展股份有限公司(以下簡稱“濟南高新”)在濟南市簽署了《戰略合作框架協議》。
本次《戰略合作協議》的簽署,有利於充分發揮公司與濟南高新雙方在各自領域的資源優勢,進一步推動雙方長期、全面、深入的合作,有利於公司與濟南高新建立長期戰略合作伙伴關係,推動公司在醫療領域的業務開拓,促進公司可持續發展,進一步增強公司綜合實力及整體競爭力,《戰略合作協議》約定的事項符合公司長遠戰略規劃和全體股東利益。本次《戰略合作協議》的簽署預計不會對公司2021年度業績構成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.